دورية أكاديمية

Dual biomarkers-activatable hollow MnO 2 -Based theranostic nanoplatform for efficient breast cancer-specific multisite fluorescence imaging and synergistic therapy.

التفاصيل البيبلوغرافية
العنوان: Dual biomarkers-activatable hollow MnO 2 -Based theranostic nanoplatform for efficient breast cancer-specific multisite fluorescence imaging and synergistic therapy.
المؤلفون: Ning J; Henan Joint International Research Laboratory of Environmental Pollution Control Materials, College of Chemical and Molecular Sciences, Henan University, Kaifeng, 475004, China., Hu G; Henan Joint International Research Laboratory of Environmental Pollution Control Materials, College of Chemical and Molecular Sciences, Henan University, Kaifeng, 475004, China., Wu T; Henan Joint International Research Laboratory of Environmental Pollution Control Materials, College of Chemical and Molecular Sciences, Henan University, Kaifeng, 475004, China., Zhao Y; Henan Joint International Research Laboratory of Environmental Pollution Control Materials, College of Chemical and Molecular Sciences, Henan University, Kaifeng, 475004, China., Nie Y; Henan Joint International Research Laboratory of Environmental Pollution Control Materials, College of Chemical and Molecular Sciences, Henan University, Kaifeng, 475004, China. Electronic address: ymnie@henu.edu.cn., Zhou Y; Henan Joint International Research Laboratory of Environmental Pollution Control Materials, College of Chemical and Molecular Sciences, Henan University, Kaifeng, 475004, China. Electronic address: zhouyanmei@henu.edu.cn.
المصدر: Analytica chimica acta [Anal Chim Acta] 2024 May 15; Vol. 1303, pp. 342521. Date of Electronic Publication: 2024 Mar 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0370534 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4324 (Electronic) Linking ISSN: 00032670 NLM ISO Abbreviation: Anal Chim Acta Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam : Elsevier
Original Publication: Amsterdam.
مواضيع طبية MeSH: DNA, Catalytic* , Neoplasms* , Carbocyanines*, Precision Medicine ; Manganese Compounds ; Oxides ; Optical Imaging ; Biomarkers
مستخلص: Background: Theranostic nanoplatforms with integrated diagnostic imaging and multiple therapeutic functions play a vital role in precise diagnosis and efficient treatment for breast cancer, but unfortunately, these nanoplatforms are usually stuck in single-site imaging and single mode of treatment, causing unsatisfactory diagnostic and therapeutic efficiency. Herein, a dual biomarkers-activatable facile hollow mesoporous MnO 2 (H-MnO 2 )-based theranostic nanoplatform, DNAzyme@H-MnO 2 -MUC1 aptamer (DHMM), was constructed for the simultaneous multi-site diagnosis and multiple treatment of breast cancer.
Results: The DHMM acted as an integrated diagnostic and therapeutic nanoplatform that realizes multi-site fluorescence imaging-guided high-efficient photothermal/chemodynamic/gene synergistic therapy (PTT/CDT/GT) for breast cancer. The H-MnO 2 exhibits high loading capacity for Cy5-MUC1 aptamer (3.05 pmoL μg -1 ) and FAM-DNAzyme (3.37 pmoL μg -1 ), and excellent quenching for the probes. In the presence of MUC1 on the cell membrane and GSH in the cytoplasm, Cy5-MUC1 aptamer and FAM-DNAzyme was activated triggering dual-channel fluorescence imaging at different sites. Moreover, the self-supplied Mn 2+ was further supplied as DNAzyme cofactors to catalytic cleavage intracellular EGR-1 mRNA for high-efficient GT and stimulated the Fenton-like reaction for CDT. The H-MnO 2 also showcases a favorable photothermal performance with a photothermal conversion efficiency of 44.16%, which ultimately contributes to multi-site fluorescence imaging-guided synergistic treatment with an apoptosis rate of 71.82%.
Significance: This dual biomarker-activatable multiple therapeutic nanoplatform was realized multi-site fluorescence imaging-guided PTT/CDT/GT combination therapy for breast cancer with higher specificity and efficiency, which provides a promising theranostic nanoplatform for the precision and efficiency of breast cancer treatment.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: Breast cancer; Hollow mesoporous MnO(2); Multi-site Fluorescence imaging; Synergistic therapy; Theranostic nanoplatform
المشرفين على المادة: 0 (cyanine dye 5)
0 (DNA, Catalytic)
0 (Manganese Compounds)
0 (Oxides)
0 (Biomarkers)
0 (Carbocyanines)
تواريخ الأحداث: Date Created: 20240412 Date Completed: 20240415 Latest Revision: 20240509
رمز التحديث: 20240510
DOI: 10.1016/j.aca.2024.342521
PMID: 38609263
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-4324
DOI:10.1016/j.aca.2024.342521